<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; clinical trial</title>
	<atom:link href="http://www.tapanray.in/tag/clinical-trial/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Changing Doctors’ Practice Dynamics With Covid-19 And Beyond</title>
		<link>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-doctors-practice-dynamics-with-covid-19-and-beyond</link>
		<comments>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/#comments</comments>
		<pubDate>Mon, 11 May 2020 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dynamic]]></category>
		<category><![CDATA[face-to-face]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[practice]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10067</guid>
		<description><![CDATA[Unexpectedly, the answer to an onerous question surfaced just around a year’s time. In my article on this blog, written on April 08, 2019, I raised a question &#8211; “Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?” Interestingly, an unexpected and abrupt turn of &#8230; <a href="http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Facet of ‘Data Integrity’ With Novel Therapy… And Much Beyond</title>
		<link>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond</link>
		<comments>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/#comments</comments>
		<pubDate>Mon, 30 Sep 2019 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AveXis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[cherry-picking]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9728</guid>
		<description><![CDATA[The peril of breach of data integrity involving a top Indian pharma player, jolted many, probably for the first time, on September 17, 2008. On that day, the USFDA, reportedly, issued two ‘Warning Letters’ and an ‘Import Alert’. These were related to &#8230; <a href="http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma And Healthcare: Mounting ‘Trust Deficit’ In Post Halcyon Days</title>
		<link>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days</link>
		<comments>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/#comments</comments>
		<pubDate>Mon, 01 Sep 2014 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[American]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[deficit]]></category>
		<category><![CDATA[disillusionment]]></category>
		<category><![CDATA[Doctored]]></category>
		<category><![CDATA[George Wilhelm Herman Emanuel Merck]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Healthcheck]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jauhar]]></category>
		<category><![CDATA[kickbacks]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Moody]]></category>
		<category><![CDATA[mounting]]></category>
		<category><![CDATA[NDTV]]></category>
		<category><![CDATA[operation]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[sting]]></category>
		<category><![CDATA[Sundeep]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[unbothered]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5795</guid>
		<description><![CDATA[Although a radical transformation in the field of medicine and path breaking advances of medical sciences are in progress, the healthcare system as whole, including the pharma industry, as voiced by many, is fast losing its human touch and values. &#8230; <a href="http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-and-healthcare-mounting-trust-deficit-in-post-halcyon-days/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Slugfest in Pharma Land: Isn&#8217;t &#8216;The Pot Calling the Kettle Black?&#8217;</title>
		<link>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black</link>
		<comments>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/#comments</comments>
		<pubDate>Mon, 29 Jul 2013 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Barometer]]></category>
		<category><![CDATA[bells]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[bribery]]></category>
		<category><![CDATA[calling]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Collusive]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[fire]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Institutions]]></category>
		<category><![CDATA[intolerance]]></category>
		<category><![CDATA[kettle]]></category>
		<category><![CDATA[KPMG]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Panel]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[quotient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[scientist]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[slugfest]]></category>
		<category><![CDATA[smoke]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3022</guid>
		<description><![CDATA[Close on the heels of detention of a British Citizen, an American citizen too has  been reportedly detained, for the first time, by the Chinese Government in connection with unfolding mega corruption scandal in the country&#8217;s pharma industry involving even &#8216;third party&#8217;. A slugfest &#8230; <a href="http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/slugfest-in-pharma-land-isnt-the-pot-calling-the-kettle-black/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Business Ethics, Values and Compliance: Walking the Talk</title>
		<link>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=business-ethics-values-and-compliance-walking-the-talk</link>
		<comments>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/#comments</comments>
		<pubDate>Mon, 26 Dec 2011 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[Walking]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=156</guid>
		<description><![CDATA[Wish you and your family all happiness, prosperity, peace and good health in the brand new year 2012 Business Ethics, Values and Compliance: Walking the Talk Ethical business conduct and value standards, especially of medium, large to very large corporations &#8230; <a href="http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/business-ethics-values-and-compliance-walking-the-talk/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
